JTE 151

Drug Profile

JTE 151

Alternative Names: JTE-151

Latest Information Update: 13 May 2016

Price : $50

At a glance

  • Originator Orphagen Pharmaceuticals
  • Developer Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Hypersensitivity

Most Recent Events

  • 02 May 2016 Discontinued - Phase-I for Hypersensitivity (PO)
  • 02 May 2016 Discontinued - Phase-I for Autoimmune disorders (PO)
  • 30 Oct 2014 Phase-I development is ongoing in Autoimmune disorders & Hypersensitivity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top